ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2153

Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience

Pavneet Kaur1, Mayank Goyal2, Shivaprasad P Mohankumar2, Lamk Kidyani2, Sanjeev Kumar2, Saurabh Gupta3, Sivasubramanian Ramakrishnan2 and Narendra Bagri4, 1All India Institute of Medical Sciences, New Delhi, India, 2AIIMS, New Delhi, India, New Delhi, Delhi, India, 3All India Institute of Medical Sciences, New Delhi, Delhi, 4ALL INDIA INSTITUTE OF MEDICAL SCIENCES, New Delhi, Delhi, India

Meeting: ACR Convergence 2025

Keywords: Pediatric rheumatology, Subclinical Cardiovascular Disease, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Coronary artery abnormalities (CAA) are a dreaded yet potentially preventable stigmata of Kawasaki disease (KD). Giant CAA are rare but at higher risk of complications and adverse outcomes. We aimed to evaluate the medium-term outcomes of children with KD with giant coronary aneurysms (Z score >10).

Methods: KD cases registered in our tertiary care centre were retrospectively reviewed, and data of children with giant CAA was analysed.

Results: Of the 34 KD cases in our register (2018-2024), we encountered 5 children (14.7%) with giant coronaries. All children presented as incomplete KD, with delayed immunomodulation and IVIg resistance. One patient had extensive systemic vascular involvement beyond the coronaries. The high proportion of children with giant coronaries as opposed to the reported literature might be due to a referral bias. The diagnosis of KD and initiation of immunomodulation took a median (IQR) of 12 (10-14) days. All received IVIg and oral steroids, with IV methylprednisolone pulse in two. All but one received primary intensification with Infliximab. CAAs persisted in all, noted during the 22 patient-years of follow-up. There was one mortality owing to a cardiovascular event. Our experience, although limited, was concordant with published literature suggesting that male sex, aneurysms at onset, delayed IVIG therapy and IVIg resistance are heralds of giant CAAs in KD. Similarly, systemic vascular involvement was associated with a poor outcome.

Conclusion: Incomplete KD may have a high propensity to develop giant coronaries, possibly refractory to immunomodulation. As is evident in our series, delayed diagnosis and immunomodulation (12 (10-14) days) are important factors determining CAA prognosis. Although rare, giant and systemic arterial aneurysms in KD are life-threatening and difficult to manage. They may progress despite appropriate immunomodulation.

Supporting image 1CT images of children with Kawasaki disease with giant coronaries

Supporting image 2Series of children with Kawasaki disease with giant coronaries


Disclosures: P. Kaur: None; M. Goyal: None; S. P Mohankumar: None; L. Kidyani: None; S. Kumar: None; S. Gupta: None; S. Ramakrishnan: None; N. Bagri: None.

To cite this abstract in AMA style:

Kaur P, Goyal M, P Mohankumar S, Kidyani L, Kumar S, Gupta S, Ramakrishnan S, Bagri N. Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/giant-coronaries-in-children-with-kawasaki-disease-a-single-centre-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/giant-coronaries-in-children-with-kawasaki-disease-a-single-centre-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology